Sanofi(US:SNY) Zheng Quan Ri Bao Wang·2025-07-16 10:50Core Viewpoint - Sanofi showcased its commitment to the Chinese market and patients at the third China International Supply Chain Promotion Expo, emphasizing its achievements in high-quality manufacturing, supply chain innovation, and patient health empowerment [1][4]. Group 1: Company Commitment and Achievements - Sanofi has been deeply rooted in the Chinese market for over 40 years, establishing a comprehensive ecological value chain that includes local R&D, manufacturing, and patient services [4]. - This year marks the 30th anniversary of Sanofi's local manufacturing in China, highlighting its ongoing commitment to enhancing high-quality production capabilities and responding to market needs [4]. - The company aims to support the "Healthy China" vision by making innovative drugs and vaccines accessible to a larger population [4][6]. Group 2: Innovations and Product Development - At the expo, Sanofi presented a "traceability journey" of flu vaccine production, showcasing its global collaboration and local supply chain advantages [5]. - The company highlighted nine breakthrough products across key disease areas, including immunology, respiratory, cardiovascular, transplantation, oncology, and rare diseases, demonstrating a comprehensive "immunization innovation chain" [5]. - Sanofi has established four R&D centers in Beijing, Shanghai, Suzhou, and Chengdu, contributing to over 90% of its global synchronized development projects, including 12 potential blockbuster products [5]. Group 3: Focus on Healthcare Accessibility - In response to national policies aimed at improving drug accessibility, Sanofi is committed to promoting equitable healthcare services and building a future where everyone can enjoy health benefits [6].